Breaking News - Candlesense

FLYW Investors Have Opportunity to Lead Flywire Corporation Securities Fraud Lawsuit

(NASDAQ:FLYW) NEW YORK, Aug. 30, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Flywire Corporation (NASDAQ: FLYW) between February...

When is the lawsuit expected to be resolved, and what are the possible outcomes that could drive the stock's future performance? What is the estimated exposure or potential settlement cost for Flywire, and how does it compare to the company's market capitalization? How could the potential securities fraud lawsuit affect Flywire's short-term stock price and volatility?

Symbol: FLYW

Lawsuits

17 days ago

Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension

(RO) Basel, 30 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam (Nasdaq: ALNY) today announced the decision to initiate a Phase III cardiovascular outcomes trial (CVOT) to evaluate the ...

What are the regulatory, reimbursement, and revenue forecast implications if the trial demonstrates a significant reduction in major adverse cardiovascular events? How does zilebesiran’s efficacy, safety, and RNAi mechanism compare to existing hypertension treatments and competing pipeline candidates from other pharma companies? What is the anticipated timeline, enrollment size, and potential market impact of the Phase III CVOT for zilebesiran on Roche and Alnylam’s valuations?

Symbol: RO

Clinical trials

17 days ago

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

(NASDAQ:ALNY) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outc...

How does the KARDIA Phase 2 data and upcoming Phase 3 trial position zilebesiran against other RNA‑i or cardiovascular‑focused competitors in terms of market share and revenue potential? What are the anticipated timelines for data read‑out and potential FDA/EMA submission, and how could those milestones affect valuation? How will the initiation of the Phase 3 CVOT for zilebesiran influence Alnylam's stock momentum and trading volume?

Symbol: ALNY

Clinical trials

17 days ago

Read more businesswire

Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension

(NASDAQ:ALNY) SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam (Nasdaq: ALNY) today announced the decision to initiate a...

What timelines and milestones (e.g., trial enrollment, data readout) should traders monitor for price volatility and catalyst events? What are the potential competitive risks from other RNAi or hypertension therapies in development, and how might they influence market share? How will the initiation of a Phase III CVOT for Zilebesiran affect Alnylam's revenue forecasts and valuation multiples?

Symbol: ALNY

Clinical trials

17 days ago

Read more businesswire

Rosen Law Firm Encourages Vera Bradley, Inc. Investors to Inquire About Securities Class Action Investigation - VRA

(NASDAQ:VRA) NEW YORK, Aug. 30, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Vera B...

Is there precedent for similar allegations in the fashion accessories sector, and how did those cases influence investor sentiment and share price performance? What potential financial exposure could arise from a possible settlement or judgment, and how would that impact earnings forecasts? How might the securities class action investigation affect Vera Bradley's short‑term stock volatility and liquidity?

Symbol: VRA

Lawsuits

17 days ago

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

(NASDAQ:AMRN) -- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High-Risk or Very High-Risk Patients Based on REDUCE-IT -...

Are there any upcoming regulatory, reimbursement, or pricing developments that could amplify or constrain revenue growth from the newly emphasized indications? What are the implications of the ESC guideline endorsement for VASCEPA/VAZKEPA's market share versus competing EPA/DHA or PCSK9 therapies? How will the highlighted REDUCE-IT sub‑analyses affect Amarin's valuation and short‑term stock momentum?

Symbol: AMRN

Clinical trials

17 days ago

Bybit x Santiment DeFi Report: Platform Tokens Shine As MNT Sees Over $1M Whale Transactions

(MNT) DUBAI, UAE, Aug. 30, 2025 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume, has released a DeFi report in collaboration with crypto market intellige...

What could the highlighted performance of platform tokens like MNT mean for the broader DeFi sector, and how might it shift capital allocation between competing Layer‑1 and Layer‑2 tokens? How does the influx of large MNT holders affect the token's on‑chain metrics such as staking participation, supply concentration, and liquidity pools? Will the $1M+ whale transactions in MNT trigger a short‑term price rally or cause sell‑pressure as whales unwind positions?

Symbol: MNT

Defi

17 days ago

Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine

(NASDAQ:CYTK) Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol

How does aficamten’s efficacy and safety profile compare to existing HCM therapies and other pipeline candidates from competing biotech firms? What are the anticipated timelines for FDA approval and commercialization of aficamten, and how might that influence the company's revenue projections? How will the positive MAPLE-HCM trial results affect CYTK's short‑term stock momentum and trading volumes?

Symbol: CYTK

Clinical trials

17 days ago

Merck Provides New Results for VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction

(NYSE:MRK) RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Provides New Results for Vericiguat in Patients with Chronic Heart Failure and Reduced Ejection Fraction. Results presented at ESC 2025

How does VERQUVO® compare to existing heart‑failure therapies and competitors' pipelines in terms of efficacy and market potential? What are the timelines for regulatory approval and market launch of VERQUVO® based on these results? How will the new VERQUVO® trial results affect Merck's stock price in the short term?

Symbol: MRK

Clinical trials

17 days ago

Read more businesswire

$2 Billion Lower Amber Energy Bid Recommended by Special Master in CITGO Sale Process

(GRZ) PEMBROKE, Bermuda--(BUSINESS WIRE)--Gold Reserve Ltd. (TSX.V: GRZ) (BSX: GRZ.BH) (OTCQX: GDRZF) (“Gold Reserve” or the “Company”) announces that its Delaware subsidiary, Dalinar Energy Corpor...

What are the potential downstream impacts on the oil and gas sector, especially regarding refinery capacity and regional supply dynamics? How does this bid compare to previous offers and the valuation expectations for PDV Holding and CITGO assets? What effect will the recommendation of a $2 billion lower Amber Energy bid have on Gold Reserve's share price and investor sentiment?

Symbol: GRZ

Mergers

17 days ago

Read more businesswire